Tolbutamide infused into the chronically catheterized sheep fetus produced significant secretion of insulin. An optimal dose range of 100-200 mg/kg estimated fetal weight was demonstrated. Paired tolbutamide and glucose infusions using a square wave technique demonstrated that although early phase insulin secretion is diminished in the fetus, this is not due to an absolute deficiency of stored insulin. Tolbutamide produced peak insulin concentrations of 51.6 2 9.0 pu/ml by 20 min postinfusion in the fetus. When similar tolbutamide infusions were performed in neonatal lambs, qualitatively similar insulin response curves were demonstrated although peak insulin levels were much greater (260 * 70 pu/ml at 20 min).
Summary
Tolbutamide infused into the chronically catheterized sheep fetus produced significant secretion of insulin. An optimal dose range of 100-200 mg/kg estimated fetal weight was demonstrated. Paired tolbutamide and glucose infusions using a square wave technique demonstrated that although early phase insulin secretion is diminished in the fetus, this is not due to an absolute deficiency of stored insulin. Tolbutamide produced peak insulin concentrations of 51.6 2 9.0 pu/ml by 20 min postinfusion in the fetus. When similar tolbutamide infusions were performed in neonatal lambs, qualitatively similar insulin response curves were demonstrated although peak insulin levels were much greater (260 * 70 pu/ml at 20 min).
A fall in plasma glucose was demonstrated in both fetal and neonatal lambs (to 75 and 3% of control values, respectively) by 60 min after tolbutamide infusion. In the fetus, this fall was not associated with changes in maternal glucose concentration.
not fetal insulin is stored in sufficient quantities to allow early release. The fetal metabolic response to endogenous insulin secretion was observed under these conditions.
METHODS
Seven pregnant ewes between 110-135 days of gestation (term gestation in the sheep is 147 days) were studied. IV sodium pentobarbital and spinal anesthesia (15 mg pontocaine) were administered preoperatively. Indwelling polyvinyl chloride catheters were inserted into a fetal pedal artery and vein, into the maternal femoral artery, and then tunneled subcutaneously to the mother's flank. Postoperative care and feeding were performed as previously described (12) . Experiments were not performed until after a 4 5 day recovery period when the animals were being fed ad libitum.
TOLBUTAMIDE DOSE RESPONSE

Speculation
The maturation of early phase insulin secretion in the neonate may involve a variety of factors beyond simple storage of insulin. The ability of the neonate to respond briskly to alterations in plasma glucose may be highly significant in an adaptation to "feast-fast" conditions. The hypoglycemia produced in response to endogenously secreted insulin in the fetus and neonate is consistent with insulin's role in accelerating glucose uptake and utilization.
Insulin has been identified in pancreatic islets of a number of mammalian species relatively early in gestation (24) . Willes et al. (28) and Sodoyez-Goffaux et al. (27) have demonstrated increasing insulin storage in fetal pancreatic tissue proportional to gestational age. In the adult, secretion of insulin in response to a constant glucose stimulus occurs in a biphasic mode with early and late peaks (8) . Recently, Blazquez et al. (3) and Philipps et al. (23) have shown an absence or diminution in the early phase of insulin secretion in response to fetal glucose elevation. Yet the newborn lamb and other species of newborns exhibit relatively brisk biphasic insulin responses during glucose infusion shortly after birth (1, 18) .
Tolbutamide is a well known insulin secretogogue that appears to release stored insulin from the / 3 cell by a mechanism different from that of glucose (10, 15) although a final common pathway of elevation of cyclic adenosine 3', 5'-monophosphate (c-AMP) has been implicated (1 1). Tolbutamide has been used in vivo and in vitro fetal preparations with conflicting results (9, 20, 27) . It is reported to have few side effects on peripheral tissues (16) , although these effects have not been extensively studied in the fetus and neonate.
Tolbutamide was infused into chronically catheterized fetal and neonatal sheep to determine whether or not fetal reactivity to this sulfonyl urea does exist in vivo, and if so, to determine whether or Varying doses of tolbutamide were infused into two fetal lambs not utilized in subsequent experiments. Tolbutamide (29) was infused via the fetal venous catheter in doses of 50, 100, 200, 300, and 400 mg/kg estimated fetal weight. Tolbutamide was dissolved in normal saline such that all infusions were accomplished at a volume of 10 ml given slowly by hand over 60 sec. Serial infusions were performed only after a recovery period of at least 48 hr after the last infusion. Plasma arterial samples for glucose and insulin were obtained twice in the 30 min preceding infusion and then at I%, 3, 5, 10, 20, 30, 60, 90 , and 120 rnin postinfusion. Maternal arterial glucose and insulin samples were obtained during the control period and at 30, 60, and 120 min postinfusion to assess possible changes in maternal homeostasis.
FETAL GLUCOSE INFUSION
Five pregnant ewes between 110-135 days of gestation were studied. Glucose was infused into the fetal venous catheter to produce an instantaneous elevation in fetal plasma glucose to 50 mg/dl above control values. A loading dose of 10% sterile glucose in water was given over 1 min via syringe pump followed by a constant infusion for 60 rnin. The dosage of glucose was calculated as previously reported (23) . Control fetal samples for plasma arterial glucose and insulin were obtained twice in the 30 min preceding infusion and at I%, 3, 5, 10, 20, 30, and 60 min during infusion. A total of nine infusions were performed at gestational ages 120-140 days (Table I) . Maternal glucose and insulin samples were obtained as in the tolbutamide dose response experiments.
FETAL TOLBUTAMIDE INFUSION
Tolbutamide was infused as in the dose response experiments at a dose of 200 mg/kg estimated fetal weight. Each tolbutamide infusion was paired to a glucose infusion which had been performed between 24-96 hr previously. Therefore, a total of nine paired infusions were performed in five fetal lambs. Fetal and 
LAMB TOLBUTAMIDE INFUSION
Four healthy newborn lambs from the fetal preparations above were operated on within 24 hr after birth. Femoral venous and arterial catheters were placed after local xylocaine (1%) anesthesia. Venous infusions were performed between 2-5 days of age. No attempt was made to control the time of feeding before infusion. Tolbutamide at a dose of 100 mg/kg of body weight was infused over I min. Blood for plasma glucose and insulin was withdrawn as in the previous tolbutamide infusions via femoral artery catheter.
BIOCHEMICAL STUDIES
Blood samples for glucose determinations were withdrawn and transferred to EDTA-coated tubes and then centrifuged for 5 min. Plasma was withdrawn and measured within 30 rnin of sampling utilizing the glucose analyzer glucose oxidase method (30). Blood samples for insulin were withdrawn and placed in chilled polyethylene tubes each containing 10 units of heparin. These were centrifuged, the plasma withdrawn, and the samples stored at -20 C until time of analysis. Insulin was measured by radioimmunoassay using a modification (23, 31) of the method of Morgan and Lazarow (21) . Each assay consisted of all samples from one animal in order to avoid interassay variability.
STATISTICAL METHODS
Results are expressed as mean f SEM. Statistical significance was assessed with the paired Student's t test.
RESULTS
A typical tolbutamide dose response curve in the fetal sheep is shown in Figure I . Brisk elevations in plasma insulin were seen with the maximum response noted between 100-200 mg/kg estimated fetal weight. A dose of 300 mg/kg yielded a quantitatively lower response with a relatively long latent period. One infusion (Table I ) of 400 mg/kg yielded no insulin response and may have contributed to fetal demise 24 hr postinfusion.
The pooled results of the nine paired fetal glucose and tolbutamide infusions are presented in Figures 2 and 3 . Glucose infusion produced a rough square wave with elevation in plasma glucose to about 40 mg/dl above baseline values (Figure 2 ). Plasma insulin concentration rose significantly only after 5 rnin of infusion (P < 0.01) but peak values (54.4 f 9.6 pu/ml) were not obtained until 20-30 rnin of infusion. Mean peak insulin concentration was approximately three times the control value.
The insul&-response to fetal tolbutamide infusion was more rapid, a significan't elevation (P < 0.02) being demonstrated by l Yz rnin ~ostinfusion ( Figure 3 ). Peak insulin concentrations were achieved by 20 rnin postinfusion (mean peak concentrations of 5 1.6 f 9.0 pu/ml), and were similar to those in the glucose infusion experiments. The plasma insulin concentration remained significantly elevated until 120 rnin postinfusion when values had returned to baseline. No relationship was found between fetal gestational age at time of infusion and peak insulin concentration achieved. Baseline fetal arterial blood gases were performed in five out of the seven animal preparations before and after tolbutamide infusion. Results were consistently in the normal range, implying normal fetal oxygenation. Changes in plasma glucose during tolbutamide infusion were assessed at 30 and 60 rnin in each maternal-fetal pair. Although no consistent changes in maternal glucose concentration occurred, fetal plasma glucose fell 2.6 f 0.9 mg/dl from control values by 30 rnin of infusion (P < 0.05) and 5.1 f 1.2 mg/dl by 60 rnin of infusion (P c 0.01). This represents a 25% reduction in fetal RESPONSE TO GLUCOSE AND TOLBUTAMIDE INFUSIONS plasma glucose concentration after tolbutamide infusion. When 260 these results were subjected to paired t test analysis to assess the effect of individual changes in maternal glucose concentration on
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each individual fetal-maternal pair, no such effect was found (P 220-> 0.1). No correlation was found between the fall in fetal glucose zooand peak fetal insulin levels achieved. Figure 4 depicts the response of the four neonatal lambs to tolbutamide infusion. As in the fetal infusions, a brisk rise in plasma insulin was noted by 1 % min postinfusion. Peak insulin levels. however. were higher and somewhat more variable. being achieved by 10-30 min postinfusion (maximum concentration = 260 f 70 pu/ml at 20 min). No correlation was found between initial plasma glucose concentration and peak insulin level achieved. The plasma glucose response was similar to those in the fetal human (9) or rat (27) pancreas demonstrated no significant insulin release in response to tolbutamide. Yet Lambert et al. (14) using an in vitro fetal rat preparation demonstrated significant insulin release in response to the addition of tolbutamide to the culture medium. Mintz et al. (20) using the catheterized fetal rhesus monkey noted elevations of fetal insulin in two out of three fetuses receiving tolbutamide.
In the present study, tolbutamide was infused into the chronically catheterized fetal lamb and caused significant elevations in plasma insulin in all animals studied. The fetal dose response curve was qualitatively similar to those reported in the adult human (10) and rat (15) in that an optimal dose range exists, above which no further increment in insulin resmnse can be seen. Likewise, a characteristic lag time before peak eievation in insulin concentration was demonstrated in both the fetal and neonatal lamb.
The typical biphasic insulin response to glucose infusion (8) is diminished in the sheep fetus but appears within several days after birth (23) . Tolbutamide was chosen to investigate this basic difference between the fetus and neonatal lamb. Tolbutamide acts primarily on the early phase of insulin secretion by releasing stored insulin (8) . The mechanism for induction of secretion has recently been demonstrated to be intimately associated with elevation of intracellular c-AMP in the pancreatic islet (5) . In this respect, it is similar in mechanism of action to that of glucose on the /3 cell (I I). Tolbutamide inhibits islet ~hosphodiesterase activity (5) and may also stimulate the activiiy of'adenylcyclase (13) . However. the insulin secretorv resmnse after tolbutamide differs from glucose in being monopiasicind in having a different latent period before secretion (15) . Unlike glucose, it has been demonstrated that tolbutamide does not induce insulin synthesis (15) and no second phase is seen with tolbutamide even though intracellular c-AMP levels remain elevated.
The rapid elevation in fetal plasma insulin after tolbutamide implies significant availability of stored insulin. It, therefore, is unlikely that an absolute deficiency of stored insulin can account for the failure of early insulin release in response to fetal glucose infusion. Paired glucose and tolbutamide infusions were undertaken to avoid the possibility that tolbutamide might induce lasting change in the kinetics of fetal insulin secretion. No such induction was demonstrated when glucose infusions were I-epeated after tolbutamide.
One possible explanation for the relative diminution in early phase insulin secretion after glucose infusions might be the relatively lower blood sugar of the fetal lamb as compared with the neonate. Bassett et 01 (2) have demonstrated in h r o that fetal lamb pancreas exhibits a sigmoidal dose response curve similar to those of other species (25) when incubated in varying concentrations of glucose. This response was maximal at 100 mg/dl glucose concentration. However, when fetal glucose infusions were performed in three fetal lambs designed to elevate plasma glucose to levels in excess of 100 mg/dl (range 100-150 mg/dl), no early phase could be demonstrated. Peak insulin values, however, were substantially above those where lesser concentrations of glucose were achieved.
Infusions of tolbutamide into the neonatal lamb demonstrated qualitatively similar insulin response curves as those in the intrauterine experiments. Although the peak insulin concentrations achieved were five-fold higher in the neonatal lambs, blood glucose was also considerably higher. Likewise, tolbutamide concentrations were not measured and, thus, no statement can be made regarding quantitative changes in insulin secretion after fetal vs. neonatal tolbutamide infusions. However, although the fetal Dancreatic response to glucose infusion is characterized by its lac'k of brisk release of stored insulin, the responses of the fetus and neonate to tolbutamide are quite similar. Because both glucose and tolbutamide-induced insulin secretion utilize a common biochemical pathway with elevations of islet c-AMP and influx of calcium, other more basic changes must be invoked to explain the appearance of early phase insulin secretion in response to glucose after birth. Possible factors such as islet cell receptor changes (22) . intracellular calcium flux (17) , islet electrical activity (19) . proinsulin content or the influence of gastrointestinal hormones after feeding should be considered.
Endogenous insulin secretion in the fetal and neonatal lamb was associated with a characteristic fall in plasma glucose between 30 and 60 min after initial elevation of insulin levels. Although, in the steady state, there is a linear relationship between fetal and maternal blood glucose (7), the fall in fetal plasma glucose after tolbutamide infusion was entirely independent of changes in maternal glucose concentration. ~harmacolo~ic doses of exogenous insulin have been shown to cause hypoglycemia (6) and to increase glucose utilization (26) when infused into the fetal lamb. A recent study (4) suggests some correlation between fetal glucose utilization and plasma insulin concentration when more physiologic concentrations (<I00 pu/ml) of insulin were achieved with infusion.
No direct evidence for a fetal metabolic response to endogenous insulin secretion, however, is presently available. Although no statement can be made regardGg a quantitative measurement of fetal glucose uptake after tolbutamide, the time course of the consequent hypoglycemia suggests that endogenous insulin secretion is the causative factor.
